Results 21 to 30 of about 10,879 (228)

Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals

Arab Journal of Gastroenterology, 2022
Background and Study Aims Currently, there is no therapy approved for COVID-19. We evaluated the efficacy and safety of sofosbuvir/ledipasvir and nitazoxanide for the treatment of patients with COVID-19 infection. Patients and Methods A multicenter, open-
M. Medhat, Mohamed El-Kassas, Haidi Karam-Allah, Ahmed Al Shafie, S. Abd-Elsalam, Ehab F. Moustafa, S. Hassany, M. Salama, Mohamed S. Abd Elghafar, Hamdy Sayed, M. Badr, Dalia T. Kamal, Ahmed Shamseldeen, Ashima'a Ossimi, Inas Moaz, Hossam El-deen Esmael, Azza M Ezz Eldin, S. Ezzat, H. Abdelghaffar, Khaled Abdelghaffar   +19 more
semanticscholar   +1 more source

Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy

Journal of Pediatric Gastroenterology and Nutrition - JPGN, 2022
Objectives: In children with hematological malignancies, chronic hepatitis C virus (HCV) infection has been associated with more rapid liver disease progression and higher risk of malignancy relapse due to chemotherapy interruption.
M. El-Sayed, F. Ebeid, A. Zekri, B. Massetto, K. Kersey, Fangqiu Zhang, A. Gaggar, W. Elsayed, Alaa El-Haddad   +8 more
semanticscholar   +1 more source

A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine

Vaccines, 2023
The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation.
Sneha Bansode, Pawan Kumar Singh, Meenakshi Tellis, Anita Chugh, Narendra Deshmukh, Mahesh Gupta, Savita Verma, Ashok Giri, Mahesh Kulkarni, Rakesh Joshi, Dhruva Chaudhary   +10 more
doaj   +1 more source

Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.

PLoS ONE, 2015
Ledipasvir, a direct acting antiviral agent (DAA) targeting the Hepatitis C Virus NS5A protein, exhibits picomolar activity in replicon cells. While its mechanism of action is unclear, mutations that confer resistance to ledipasvir in HCV replicon cells ...
Hyock Joo Kwon, Weimei Xing, Katie Chan, Anita Niedziela-Majka, Katherine M Brendza, Thorsten Kirschberg, Darryl Kato, John O Link, Guofeng Cheng, Xiaohong Liu, Roman Sakowicz   +10 more
doaj   +1 more source

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms

Molecules, 2020
A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM),
Essam Ezzeldin, Nisreen F. Abo-Talib, Marwa H. Tammam, Yousif A. Asiri, Abd El-Galil E. Amr, Abdulrahman A. Almehizia   +5 more
doaj   +1 more source

Treatment of Chronic HCV Infection with Direct Acting Antivirals

Central Asian Journal of Medical Sciences, 2021
Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs).
Bekhbold Dashtseren, Zulkhuu Genden, Odgerel Oidovsambuu, Anir Enkhbat, Ganbolor Jargalsaikhan, Sumiya Byambabaatar, Myammarsuren Shagdarsuren, Altankhuu Murdorj, Oyungerel Ravjir, Naranbaatar Dashdorj, Naranjargal Dashdorj, Dagvadorj Yagaanbuyant, Batbaatar Gunchin   +12 more
doaj   +1 more source

Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.

Journal of the Formosan Medical Association = Taiwan yi zhi, 2022
BACKGROUND/PURPOSE The Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) is a nationwide registry of chronic hepatitis C patients in Taiwan.
Ching-chu Lo, Chung-Feng Huang, P. Cheng, K. Tseng, Chi-Yi Chen, H. Kuo, Yi‐Hsiang Huang, C. Tai, C. Peng, Ming-Jong Bair, C.-H. Chen, M. Yeh, Chih-Lang Lin, Chun‐Yen Lin, Pei‐Lun Lee, L. Chong, Chao-Hung Hung, T. Chang, Jee‐Fu Huang, Chi‐Chieh Yang, Jui-Ting Hu, Chih-Wen Lin, Chun‐Ting Chen, Chia-Chi Wang, W. Su, T. Hsieh, Chih‐Lin Lin, W. Tsai, Tzong‐Hsi Lee, Guei-Ying Chen, Szu-Jen Wang, Chun-Chao Chang, L. Mo, Sheng-Shun Yang, Wen-Chih Wu, Chia-Sheng Huang, Chou Hsiung, Chien-Neng Kao, P. Tsai, Chen‐Hua Liu, Mei‐Hsuan Lee, Chun-Jen Liu, C. Dai, W. Chuang, Han‐Chieh Lin, J. Kao, Ming‐Lung Yu   +46 more
semanticscholar   +1 more source

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients

The Saudi Journal of Gastroenterology, 2019
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline ...
Mohammed A Babatin, Abdullah S AlGhamdi, Abdullah M Assiri, Haziz AlBiladi, Hammad S AlOthmani, Mohammed H Mogharbel, Wedad Mahallawi, Tarik Asselah, Faisal M Sanai   +8 more
doaj   +1 more source

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C. [PDF]

Int J Hepatol
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Tawara S, Watanabe A, Yamaguchi J, Omi M, Miyazaki T, Taguchi H, Kiyota R, Yamai T, Kawai S, Inoue T, Yakushijin T.   +10 more
europepmc   +2 more sources

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]

, 2015
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A., Kaur, Kirpal, Slish, Judianne   +2 more
core   +2 more sources